Comparison of safety and immunogenicity of two doses of investigational Hepatitis B virus surface antigen co-administered with an immunostimulatory Phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B Vaccine in healthy adults 18-55 years of age